Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is the first ...

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Subcutaneous Biologics Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Biologic, Type of Therapy, End User, Payment Method ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous administration of a breast cancer therapy significantly decreased treatment time compared with IV ...

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Subcutaneous Biologics Market, Industry Trends and Global Forecasts to 2035: Type of Biologic, Type of Therapy, Method of Administration, Fundamental ...

Boruzu is the first ready-to-use version of bortezomib for subcutaneous and intravenous administration in the treatment of multiple myeloma and mantle cell lymphoma. The FDA has approved Amneal ...

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational ...

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety ...

Ottawa, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The global subcutaneous biologics market size was valued at USD 1.89 billion in 2024 and is predicted to hit around USD 5.37 billion by 2034, rising at a ...